EUFOREA treatment algorithm for allergic rhinitis (Letter)

Allergic rhinitis (AR) is the most common chronic inflammatory disease, affecting an estimated 100 million Europeans (1). Despite a substantial burden on individuals, society and health economies (2), AR remains under-diagnosed, under-estimated (in terms of severity), and under-treated (3). Although effective and safe treatments exist, patients wait too long to seek medical advice, often preferring to self-manage at drug stores and at the pharmacy (4).